Akero Therapeutics (NASDAQ:AKRO) Announces Quarterly Earnings Results

Share on StockTwits

Akero Therapeutics (NASDAQ:AKRO) issued its quarterly earnings data on Monday. The company reported ($2.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($1.85), Bloomberg Earnings reports.

AKRO stock opened at $26.28 on Wednesday. Akero Therapeutics has a twelve month low of $16.06 and a twelve month high of $30.13. The stock’s 50 day moving average is $21.96.

Several analysts have issued reports on the stock. JPMorgan Chase & Co. assumed coverage on shares of Akero Therapeutics in a research report on Monday, July 15th. They issued an “overweight” rating and a $28.00 price objective for the company. Evercore ISI assumed coverage on shares of Akero Therapeutics in a research report on Monday, July 15th. They issued an “outperform” rating and a $35.00 price objective for the company. Roth Capital assumed coverage on shares of Akero Therapeutics in a research report on Monday, July 15th. They issued a “buy” rating and a $34.00 price objective for the company. Finally, Jefferies Financial Group assumed coverage on shares of Akero Therapeutics in a research report on Monday, July 15th. They issued a “buy” rating and a $28.00 price objective for the company.

In related news, Director Seth Loring Harrison purchased 900,000 shares of the firm’s stock in a transaction dated Monday, June 24th. The stock was acquired at an average price of $16.00 per share, with a total value of $14,400,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Global Strategic Fund I. Venbio purchased 250,000 shares of the firm’s stock in a transaction dated Monday, June 24th. The shares were bought at an average cost of $16.00 per share, with a total value of $4,000,000.00. The disclosure for this purchase can be found here.

About Akero Therapeutics

Akero Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease.

Featured Story: Buy Rating

Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Spotify  Holdings Lifted by Prime Capital Investment Advisors LLC
Spotify Holdings Lifted by Prime Capital Investment Advisors LLC
Inogen Inc  Expected to Announce Earnings of $0.23 Per Share
Inogen Inc Expected to Announce Earnings of $0.23 Per Share
AMN Healthcare Services, Inc.  Given Consensus Rating of “Buy” by Brokerages
AMN Healthcare Services, Inc. Given Consensus Rating of “Buy” by Brokerages
$4.09 Billion in Sales Expected for General Mills, Inc.  This Quarter
$4.09 Billion in Sales Expected for General Mills, Inc. This Quarter
Endeavour Silver Corp  Receives $2.75 Consensus Target Price from Brokerages
Endeavour Silver Corp Receives $2.75 Consensus Target Price from Brokerages
Brokerages Set Alamos Gold Inc  Target Price at $6.77
Brokerages Set Alamos Gold Inc Target Price at $6.77


© 2006-2019 Ticker Report